EP3346919A1 - Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm) - Google Patents

Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm)

Info

Publication number
EP3346919A1
EP3346919A1 EP16843738.2A EP16843738A EP3346919A1 EP 3346919 A1 EP3346919 A1 EP 3346919A1 EP 16843738 A EP16843738 A EP 16843738A EP 3346919 A1 EP3346919 A1 EP 3346919A1
Authority
EP
European Patent Office
Prior art keywords
spectral data
ptsd
subject
stress disorder
traumatic stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16843738.2A
Other languages
German (de)
English (en)
Other versions
EP3346919A4 (fr
Inventor
Carolyn E. Mountford
Scott QUADRELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Datchem Pty Ltd
Original Assignee
Translational Research Institute Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Research Institute Pty Ltd filed Critical Translational Research Institute Pty Ltd
Publication of EP3346919A1 publication Critical patent/EP3346919A1/fr
Publication of EP3346919A4 publication Critical patent/EP3346919A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4633—Sequences for multi-dimensional NMR

Definitions

  • the present invention relates to a system and method for detecting and monitoring PTSD using spectral data obtained using magnetic resonance spectroscopy.
  • PTSD is an increasingly common disorder affecting especially military personnel.
  • the traditional ways of detecting the disorder are by clinical metrics of post-concussion symptom scale, balance error scoring stem and cognitive assessment.
  • Neuropsychological evaluation includes attention related skills, new learning and memory function and intellectual functioning. These detection methods are time consuming, involve some degree of subjectivity and thus possibly misdiagnosis, and are costly.
  • FAAH fatty-acid amide hydrolase
  • a system and method for diagnosing PTSD using spectral data obtained using magnetic resonance spectroscopy.
  • the method comprises acquiring spectral data of a region of the brain of a subject, comparing the acquired spectral data with reference spectral data from normal subjects, and determining whether selected molecules in the obtained spectral data are different relative to the reference spectral data, to indicate that the subject has PTSD.
  • the invention also provides a system for detecting PTSD, and for monitoring the subject and progress of treatment.
  • the invention provides an effective and relatively objective in vivo method and system for detecting PTSD, noninvasively, in a relatively fast and robust manner which also does not require any communication, counseling or therapy with the subject, thereby reducing the added stress and trauma attendant to the traditional ways of detecting PTSD which remind subjects of the very disorder for which they are seeking treatment.
  • Figure 1 is a three dimensional graph showing 2D COSY data from subjects known to have PTSD;
  • Figure 2 is a table showing the elevated levels of certain molecules from subjects known to have PTSD; and Figure 3 is a three dimensional graph showing levels of fucose in healthy controls (upper) and subjects with PTSD, wherein the fucose I and III are diminished in the PTSD subjects relative to the controls.
  • the present invention provides a method of detecting whether a subject has Post Traumatic Stress Disorder (PTSD) comprising the steps of: acquiring spectral data of the region of a brain of a subject; comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with PTSD; and determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has PTSD based on the comparison.
  • PTSD Post Traumatic Stress Disorder
  • the selected molecules may comprise at least one of histidine, fucosylated glycans, lipids, ⁇ - Aminobutyric acid (GAB A), macro molecules (MM), glyceryphosphorylcholine (GPC), Phenylalanine (PE) and glutamate/glutamine.
  • the acquired spectral data may be L-COSY 2D spectral data.
  • the method may further comprise repeating the steps of acquiring, comparing and determining while the subject is undergoing treatment for PTSD, to determine the progress of treatment.
  • the invention also provides a system for detecting whether a subject has Post Traumatic Stress Disorder (PTSD) comprising: a spectrometer acquiring spectral data of the region of a brain of a subject; a comparator for comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with PTSD; and a processor for determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has PTSD based on the comparison.
  • the selected molecules may comprise at least one of histidine, fucosylated glycans, lipids, ⁇ - Aminobutyric acid (GAB A), macro molecules (MM), glyceryphosphorylcholine (GPC),
  • the acquired spectral data may be COSY 2D spectral data.
  • the system may comprise a memory for storing spectral data obtained from a subject from at least two different time periods, and wherein the processor compares two differently obtained spectral data to determine whether the subject is responding favorably to treatment.
  • Subjects who have been diagnosed with PTSD using conventional psychological methods can be used to develop a reference database by having their brains scanned with an MR spectrometer separate or as part of a clinical MRI scanner of a magnetic resonance spectroscopy system.
  • the system can be a 3Tesla (3T) or higher MRI scanner using a 32 or 64 or greater channel head coil.
  • the pulse sequence used may be an L-COSY either ID or 2D. Further details on how to acquire such data may be found in Ramadan S. et al., In Vivo Two Dimensional MR Spectroscopy Compares the Biochemistry of the Human Brain and Glioblastoma, and Radiology, 2011.
  • the spectral data from normal subjects will comprise a reference database in which certain molecules will have certain reference concentrations.
  • Subjects known to have PTSD by conventional diagnostic methods have been found to have different concentration of certain molecules in their brain compared to normal subjects.
  • Figure 2 comprises a Table of concentrations of certain molecules of PTSD subjects and how they differ from controls who are normal subjects. The last column of the Table shows the % difference of the molecule concentrations of the PTSD subjects relative to normal control subjects. The changes include but are not limited to those in Table 1 plus the fucosylated glycerns including Fuel and Fuc 4.
  • a subject to be evaluated for possible PTSD will undergo magnetic resonance spectroscopy of the brain to obtain the molecular concentration or ratio of the molecules listed and possibly other telltale marker molecules.
  • a determination can be made on whether the suspected subject has PTSD in an efficient and robust manner.
  • the comparison may also be made using a classifier method developed from a database.
  • Figures 1 and 3 show three dimensional results of spectra from a subject diagnosed with PTSD, and showing different concentrations of certain molecules relative to normal controls.
  • Diffuse axonal injury (DAI) from PTSD can arise from at least 10 different types of measurable deregulation or damage.
  • 2D COSY provides specific DAI chemical changes providing a non-invasive and objective diagnosis more robust than conventional diagnosis methods.
  • the invention also includes treatment methods and monitoring to determine progress of subjects in treating the disorder.
  • Personalized treatment approaches can be employed, as the diagnosis method reveals the precise chemical imbalances that need correction. For example, if the diagnosis result indicates inflammation, the condition can be treated with anti-inflammatory medications or other treatment, and periodically monitored by testing the subject to determine the rate of recovery.
  • Targeted intervention will provide early response with benefit in long-term neuropsychological and neuropsychiatric outcomes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Social Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Educational Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un système et un procédé qui identifient un trouble de stress post-traumatique au moyen de la spectroscopie par résonance magnétique (SRM) afin de mesurer les concentrations absolues et relatives de métabolites dans des régions spécifiques du cerveau dans le système nerveux central ou le cerveau. Le système et le procédé peuvent être utilisés en tant qu'outil de diagnostic pour l'évaluation d'un TSPT. Ces changements chimiques dans le cerveau des personnes souffrant de TSPT sont différents de celles souffrant de lésion crânienne, douleur chronique et d'autres états neurologiques.
EP16843738.2A 2015-09-10 2016-09-12 Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm) Withdrawn EP3346919A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216947P 2015-09-10 2015-09-10
US201562217484P 2015-09-11 2015-09-11
PCT/IB2016/001440 WO2017042635A1 (fr) 2015-09-10 2016-09-12 Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm)

Publications (2)

Publication Number Publication Date
EP3346919A1 true EP3346919A1 (fr) 2018-07-18
EP3346919A4 EP3346919A4 (fr) 2019-05-01

Family

ID=58240655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16843738.2A Withdrawn EP3346919A4 (fr) 2015-09-10 2016-09-12 Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm)

Country Status (3)

Country Link
EP (1) EP3346919A4 (fr)
AU (1) AU2016320637A1 (fr)
WO (1) WO2017042635A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043648A1 (fr) * 2017-09-01 2019-03-07 Translational Research Institute Pty Ltd As Trustee For Translational Research Institute Trust Système et procédé de détection et de surveillance de l'exposition au souffle à l'aide de spectroscopie par résonance magnétique (srm)
US11529054B2 (en) 2018-07-25 2022-12-20 The Charles Stark Draper Laboratory, Inc. Method and system for post-traumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) diagnosis using magnetic resonance spectroscopy
US20200029816A1 (en) * 2018-07-30 2020-01-30 Translational Research Institute Pty Ltd As Trustee For Translational Research Institute Trust Method and system for detecting and identifying acute stress response from traumatic exposure, its transition to post traumatic stress disorder, and monitoring subsequent therapy
WO2020084535A1 (fr) * 2018-10-24 2020-04-30 Translational Research Institute Pty Ltd As Trustee For Translational Research Institute Trust Procédé et système de surveillance de la progression du traitement d'un individu présentant une douleur aiguë, une douleur chronique, un trouble de stress aigu, une exposition au souffle ou un ptsd à l'aide de données spectrales du cerveau
US20200178889A1 (en) * 2018-12-10 2020-06-11 Translational Research Institute Pty Ltd As Trustee For Translational Research Institute Trust System and method for detecting levels of pain using magnetic resonance spectroscopy (mrs)
US20200261012A1 (en) * 2019-02-15 2020-08-20 Translational Research Institute Pty Ltd As Trustee For Translational Research Institute Trust System and method for treating and monitoring post traumatic stress disorder (ptsd)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2642919A4 (fr) * 2010-11-26 2014-10-08 Brigham & Womens Hospital Procédé d'évaluation de lésions traumatiques de la tête répétitives à l'aide de spectroscopie de résonance magnétique bidimensionnelle
US20160209428A1 (en) 2013-08-21 2016-07-21 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system

Also Published As

Publication number Publication date
EP3346919A4 (fr) 2019-05-01
WO2017042635A1 (fr) 2017-03-16
AU2016320637A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
EP3346919A1 (fr) Système et procédé de détection et de surveillance de trouble de stress post-traumatique (tspt) au moyen de la spectroscopie par résonance magnétique (srm)
Lin et al. Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy
Bonanni et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies
US7742800B2 (en) Methods and systems for detection and monitoring of neurodegenerative diseases using magnetic resonance spectroscopy
US8755862B2 (en) System and method for detecting pain and its components using magnetic resonance
Astley et al. Magnetic resonance spectroscopy outcomes from a comprehensive magnetic resonance study of children with fetal alcohol spectrum disorders
Lin et al. 1H-MRS metabolites in adults with Down syndrome: effects of dementia
AU2015231286B2 (en) Identifying different types of pain using magnetic resonance spectroscopy
Meyerhoff Brain proton magnetic resonance spectroscopy of alcohol use disorders
Brien et al. Classification and staging of Parkinson's disease using video-based eye tracking
Pimentel‐Silva et al. Interactions between in vivo neuronal‐glial markers, side of hippocampal sclerosis, and pharmacoresponse in temporal lobe epilepsy
Mahlknecht et al. Is there a need to redefine Parkinson’s disease?
Laakso et al. Decreased brain creatine levels in elderly apolipoprotein E ε4 carriers
Cheung et al. Metabolic and Structural Skeletal Muscle Health in Systemic Lupus Erythematosus–Related Fatigue: A Multimodal Magnetic Resonance Imaging Study
RU2584651C1 (ru) Способ диагностики когнитивных нарушений сосудистого происхождения при хронической ишемии мозга
Zelko et al. Regional brain volumes and cognition in childhood epilepsy: Does size really matter?
US20190125257A1 (en) System and method for detecting and monitoring post traumatic stress disorder (ptsd) using magnetic resonance spectroscopy (mrs)
AU2018326834A1 (en) System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (MRS)
US20060166270A1 (en) Detection of demyelination
US20200029816A1 (en) Method and system for detecting and identifying acute stress response from traumatic exposure, its transition to post traumatic stress disorder, and monitoring subsequent therapy
Susnjar Clinical applications of magnetic resonance spectroscopy
Zitser et al. Autonomic Dysfunction in Parasomnias of REM Sleep
Shahim et al. Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI
Özemir et al. Investigation of Magnetic Resonance Spectroscopy Findings in Patients with Absence Status Epilepticus
Hassanein Maiko Sakamoto, PhD, William Perry, PhD b, Robin C. Hilsabeck, PhD c, d, Fatma Barakat, BA e

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190403

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/055 20060101AFI20190328BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DATCHEM

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220104

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DATCHEM PTY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220517